中文

Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd.

Stand at The Fresh Sart Point, Create a New Era

Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (“SPH Kyuan Trade”) is a core pharmaceutical import and distribution company of SPH Kyuan affiliated to Shanghai Pharma, which has been listed in the Fortune Global 500 for consecutive years. Settled in Beijing Tianzhu Comprehensive Bonded Area in 2009, Kyuan Trade is a diversified large-scale comprehensive service-oriented pharmaceutical enterprise integrating imported bonded products, pharmaceutical circulation, vaccine services, digital marketing, market access and supply chain extension services, with nationwide business coverage,

Development History

2009
2010
2011-2014
2015-2018
2019
2020
2021-Todate
2009
Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. was established with a registered capital of 30 million yuan.
2010
Its ERP system has gone online, its logistics management and quality control system have been recognized by its major global multinational pharmaceutical partners, and it has won the title of Advanced Unit in Tianzhu Comprehensive Bonded Area.
2011-2014
It was awarded the title of Double A Enterprise by the General Administration of Customs in 2014, and has ranked the first in the tax amount in Tianzhu Comprehensive Bonded Area for five consecutive years. It obtained ISO9001:2008 certification in 2013.
2015-2018
In 2018, its drug sales reached RMB 3.531 billion, and it ranked the first in the tax amount for 9 consecutive years in Tianzhu Comprehensive Bonded Area. In January 2017, it started the first sales of vaccines and other new bonded warehousing businesses. In 2016, the Vaccine Business Division was transferred from Beijing Kyuan to the Kyuan Trade, further improving the national deployment of its vaccine business. In June 2015, it obtained the License for Pharmaceutical Trading, and obtained the GSP certification in December. It is one of the first authorized enterprises in Beijing Tianzhu Comprehensive Bonded Area.
2019
In January 2019, it began to change its business model, and for the first time opened a new business model for bonded enterprises in its domestic drug sales business. It newly established a wholly-owned subsidiary, namely Keyuan Xinhai (Beijing) International SCM Co., Ltd.and obtained the business license on March 14, 2019.
2020
Sales amount reached 19.01billion RMB. Passed GSP certificate renewal & AEO high-recognition enterprise re-examination. Funded Kyuan Trade Smart Pharmacy and got Pharmaceutical Trade License. Participated in the proposed proposals of the NPC in the name of Kyuan Trade for the 1st time. Operating Heart Selection cross-border platform.
2021-Todate
Sales reached RMB 20.81 billion,Registered capital increased to RMB 65 million,Obtained the Value-added Telecommunications Business License,Obtained the Food Business License,Established Shanghai and Guangzhou offices,Established a wholly-owned subsidiary, Kyuan Trade E-Commerce.

Our Values Have Deeply influenced Every SPH Kyuan Trade Person

SPH Kyuan Trade Has Maintained Rapid Growth And Sustainable Development And Won Social Recognition

We commit to the all-round development in the field of Massive Health and hopes to introduce and provide better products and services, build a more advanced global pharmaceutical supply chain system, and better serve people's health through the integration of its resources in such fields as medicines, vaccines and Massive Health products for many years. It has won many honors, such as "Double A Import and Export Enterprise of Beijing Customs", "Double-A Enterprise of General Administration of Customs" and "Grade A Enterprise of Tax-paying Credit for National Tax and Local Tax in Beijing".